Relapsed or Refractory Metastatic Colorectal Cancer – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to affect the prognosis of CRC in men adversely. About a quarter of a contributor to genetic predisposition. The development time of CRC usually lasts from several to several years; therefore, it is essential to diagnose it early in developing the disease. Previously diagnosed with cancer, a history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy may lead to colorectal cancer (CRC). Surgery encompasses the primary form of treatment for colon cancer, whereas chemotherapy is used most commonly in the adjuvant setting. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%. Clinical outcomes in mCRC have improved significantly, mainly due to the identification of molecular subtypes. The median overall survival (OS) now approximates 30 months in clinical trial populations and two years in the general population. Molecular profiling of tumors is now routinely performed to identify the approximately 40% that are RAS wild type (WT) that are susceptible to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAB) therapy.

 

The incidence of colorectal cancer (CRC) in the USA ranges from 40 to 45 cases per million population.

 

The competitive landscape of Relapsed or Refractory Metastatic Colorectal Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Relapsed or Refractory Metastatic Colorectal Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Metastatic Colorectal Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed or Refractory Metastatic Colorectal Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          GCC19CART    Innovative Cellular Therapeutics Inc.      Phase 1

2          rifluridine/Tipiracil           Taiho Oncology, Inc.     Phase 3

3          ALX148 ALX Oncology Inc.        Phase 2

4          Pembrolizumab Merck Sharp & Dohme Corp.     Phase 2

5          Fruquintinib       Hutchison Medipharma Limited  Phase 3

6          BEY1107          BeyondBio Inc.  Phase 2

7          MGD007 + MGA012      MacroGenics    Phase 2

8          PEP02  PharmaEngine  Phase 1

9          Bevacizumab    Qilu Pharmaceutical Co., Ltd.     Phase 2

10        Capecitabine     Boehringer Ingelheim     Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more